Wells Fargo’s Avalo Therapeutics AVTX Stock Holding History

Wells Fargo’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$676K	Buy	+36,576	New	+$578K	﹤0.01%	4397
2024 Q4	–	Sell	-1	Closed	-$10	–	7059
2024 Q3	$10	Hold	1	–	–	﹤0.01%	6662
2024 Q2	$12	Sell	1 -7	-88%	-$91	﹤0.01%	6605
2024 Q1	$175	Hold	8	–	–	﹤0.01%	6524
2023 Q4	$73	Buy	8 +3	+60%	+$68	﹤0.01%	6844
2023 Q3	$150	Buy	5 +4	+400%	+$179	﹤0.01%	6651
2023 Q2	$57	Hold	1	–	–	﹤0.01%	7025
2023 Q1	$277	Hold	1	–	–	﹤0.01%	6688
2022 Q4	$660	Hold	1	–	–	﹤0.01%	6308
2022 Q3	$0	Hold	1	–	–	﹤0.01%	6643
2022 Q2	$0	Sell	1 -4	-80%	-$5.35K	﹤0.01%	6783
2022 Q1	$11K	Sell	5 -10	-67%	-$25.1K	﹤0.01%	6227
2021 Q4	$72K	Buy	+15	New	+$90K	﹤0.01%	5791
2021 Q3	–	Sell	-6	Closed	-$48.6K	–	6547
2021 Q2	$62K	Sell	6 -4	-40%	-$33.5K	﹤0.01%	5470
2021 Q1	$84K	Sell	10 -5	-33%	-$47.2K	﹤0.01%	5562
2020 Q4	$114K	Hold	15	–	–	﹤0.01%	5309
2020 Q3	$98K	Buy	15 +6	+67%	+$45.1K	﹤0.01%	5274
2020 Q2	$67K	Sell	9 -3	-25%	-$21.8K	﹤0.01%	5389
2020 Q1	$87K	Hold	12	–	–	﹤0.01%	5131
2019 Q4	$193K	Hold	12	–	–	﹤0.01%	4968
2019 Q3	$118K	Sell	12 -42	-78%	-$469K	﹤0.01%	5241
2019 Q2	$853K	Buy	+54	New	+$818K	﹤0.01%	3977

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wells Fargo's AVTX Position: Q2 2026 in Review

Wells Fargo opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 36,576 shares worth $676K. The stake represents ﹤0.01% of the portfolio and ranks #4397 among its holdings. This is a return to the name: Wells Fargo previously reported a position in AVTX as recently as Q3 2024.

Wells Fargo first reported a position in AVTX in Q2 2019 and has held it in 22 quarters since. The position peaked at $853K in Q2 2019. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Wells Fargo held 36,576 shares of Avalo Therapeutics worth $676K as of Q2 2026.
Avalo Therapeutics was a new Wells Fargo position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4397 holding.
Wells Fargo first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 22 quarters since.
Wells Fargo's Avalo Therapeutics position peaked at $853K in Q2 2019.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.